Abstract
IntroductionThis is an interventional prospective clinical study which was conducted to evaluate the efficacy, safety, predictability, ocular aberrations, and flap thickness predictability of Visumax femtosecond laser (FSL) compared to Moria M2 microkeratome (MK) in mild to moderate myopia.MethodsThis study included 60 eyes who were divided into two groups. Thirty eyes in group (I) in which the flap was created with Visumax FSL, while in group II (30 eyes) the Moria M2 MK was used. Keratometric, refractive, and aberrometric measurements were compared preoperatively and 3 months postoperatively. The intraoperative subtraction pachymetry (the SP 100 Handy pachymeter (Tomey, Nagoya, Japan) was used for preoperative pachymetry and flap thickness measurement.ResultsNo significant difference was found between the two groups in regards to postoperative manifest sphere, spherical equivalent, astigmatism, safety indices nor ocular aberrations. Twenty six eyes (86.6%) in group I and 23 eyes in group II (76.6%) were within ±0.5D of the intended correction and 23 eyes (76.6%) in group I and 15 eyes in group II (50%) were within ±0.25D of the intended correction. In group I, the mean postoperative actual flap thickness was 100.12 ± 16.1 μm (81 to 122 μm), while in group II, it was 104.6 ± 20.1 μm (62 to 155 μm). The difference was statistically significant (p = 0.001).ConclusionsBoth Visumax and Moria M2 MK are safe and effective in treating myopia with no statistically significant difference in induction of ocular aberrations but with potential advantage for Visumax regarding predictability. More accurate flap thickness is achieved with Visumax femtolasik.Trial registrationThis study was retrospectively registered on 19/6/2017. Trial registration number NCT03193411, clinicalTrials.gov.
Highlights
This is an interventional prospective clinical study which was conducted to evaluate the efficacy, safety, predictability, ocular aberrations, and flap thickness predictability of Visumax femtosecond laser (FSL) compared to Moria M2 microkeratome (MK) in mild to moderate myopia
In group (I), corneal flaps were created with the Visumax FSL (Carl Zeiss Meditec, Oberkochen, Germany) while in group (II) they were created with Moria M2 MK (Moria Spherical aberrations (SA), Antony, France)
Male and female patients were included in the study if they were older than 18 years and younger than 40 years, have stable myopia up to −6.0D and astigmatism up to −3.0D determined by manifest refraction for at least 6 months, a corrected distance visual acuity of at least 20/20, and stable keratometry after cessation of soft contact lens wear for at least 2 weeks
Summary
This is an interventional prospective clinical study which was conducted to evaluate the efficacy, safety, predictability, ocular aberrations, and flap thickness predictability of Visumax femtosecond laser (FSL) compared to Moria M2 microkeratome (MK) in mild to moderate myopia. Some studies reported that creating LASIK flaps with the FSL resulted in better UDVA and faster visual recovery, lower postoperative astigmatism and trefoil, lesser degree of spherical aberration, faster recovery of corneal sensation, and some contrast sensitivity value [4, 5]. Others reported that the visual outcomes during the first 6 months after LASIK is not affected by the method of flap creation [6]. This prospective clinical study compared the Visumax FSL and the Moria M2 MK in treating myopia. The secondary outcomes were changes in keratometry and corneal aberration and flap thickness predictability
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
